FABASOFT-APPROVE
17.1.2023 14:10:37 CET | Business Wire | Press release
Primetals Technologies relies on Approve on Fabasoft PROCECO for traceable communication with customers and manufacturers. In large projects lasting up to three years, as many as 50,000 documents belonging to the plant documentation (as-built documentation) have to be exchanged securely.
Approve supports the group's “transmittal management”, i.e. the contract-relevant communication involved in the coordination of technical documents between the project management and its partners. A direct data connection to SAP P&E (Projects & Engineering Support) replaces multi-stage transmission steps via internal drives and avoids manual effort. “With Approve, we have discovered a state-of-the-art, highly customizable platform for exchanging technical documents with our customers, suppliers, and internal project members”, explains Gerhard Guger, Head of Project Coordination Casting & ESP at Primetals Technologies. For each shipping package, a structured representation of the complex content is available to users directly in the cloud-based environment.
Secure data storage and compliance
The pioneer in plant equipment attaches great importance to data security when dealing with sensitive business data and protected know-how. With data storage in Austria and a highly secure, certified technological basis, the software meets these requirements to the full. “As a secure customer portal, Approve provides project management with a transparent and extremely user-friendly environment for transferring sensitive documents. The structured view of project documents and an intelligent search function make it easier to work with large volumes of documents and ensure traceability throughout the entire duration of the project,” adds Andreas Dangl, Managing Director of Fabasoft Approve.
More detailed information in this context can be found in the case study “Efficient transfer of as-built documentation”
About Fabasoft Approve
Fabasoft Approve GmbH is a European software provider for technical data and document management in the industrial sector. Thanks to the simple adaptability via no-code/low-code, customer-specific requirements can be implemented in no time at all. The digitalization company focuses on use cases in quality management, technical documentation and transmittal management. Cross-company processes link internal and external project partners on a common platform and digitally map the entire information life cycle for industrial products. Numerous major international companies rely on the cloud-based product Approve on Fabasoft PROCECO as a “single source of truth” in their digitalization strategy.
About Primetals Technologies
Based in London, Primetals Technologies is a technological pioneer and a leading global company in the fields of engineering, plant construction and lifecycle services for the metals industry. The joint venture of Mitsubishi Heavy Industries and partners employs approximately 7,000 people worldwide.
For additional information, visit the Fabasoft Approve Press Room, www.fabasoft.com/approve, or follow us on LinkedIn and Twitter @Fabasoft.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005049/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom